Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
R&D 083 LAI
- Development stage
- Unknown
- Lead developer
- Bostal Pharma
- Modality
- Small Molecules
- Administration
- Intramuscular
01
Overview
R&D 083 LAI is a long-acting injectable (LAI) formulation of the atypical antipsychotic aripiprazole, developed by Bostal Drug Delivery. It is designed for monthly (1M) administration to treat neuroscience-related disorders, primarily schizophrenia and bipolar I disorder. The drug utilizes Bostal's proprietary drug delivery technology to provide sustained release of the active ingredient, improving patient compliance and maintaining stable therapeutic plasma levels. It is currently in Phase 2/3 clinical development, which is typically mapped to Phase 3 for tracking purposes.
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on R&D 083 LAI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on R&D 083 LAI.